Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2021-09-14 Annual Report
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Filing of Form 10-Q
Annual Report Classification · 1% confidence The document is a Form 10-Q, which is a comprehensive quarterly financial report filed with the SEC. It contains unaudited condensed consolidated financial statements, management's discussion and analysis (MD&A), and other required disclosures for the period ended June 30, 2021. Although it is preceded by a short RNS announcement header, the document itself includes the full text of the 10-Q filing, making it a primary financial report rather than just an announcement. Q2 2021
2021-09-14 English
10-Q
Interim / Quarterly Report Q2 2021
2021-09-13 English
Issue of Equity and Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the 'Issue of Equity', 'Increase to Block Listing', and 'Total Voting Rights'. It details the issuance of new common stock due to option exercises and provides a formal 'AIM Block Admission Return' as required by regulatory rules. Because the document describes changes to the company's capital structure (share issuance) and provides updated total voting rights, it falls under the 'Share Issue/Capital Change' category.
2021-09-06 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the upcoming release of their second-quarter 2021 financial results and the scheduling of a conference call. It does not contain the actual financial results, but rather serves as a notification of when those results will be published. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2021-09-02 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-11 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.